The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19).
Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or …

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …

As part of the TACTICS (Transnational Alliance for Regenerative Therapies in
Cardiovascular Syndromes) series to enhance regenerative medicine, here, we discuss the …

Morbidity and mortality from ischaemic heart disease (IHD) and heart failure (HF) remain
significant in Europe and are increasing worldwide. Patients with IHD or HF might benefit …

Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct
intramyocardial injections of adipose tissue‐derived mesenchymal stromal cells …

Heart failure (HF) is one of the leading causes of death worldwide and has reached
epidemic proportions in most industrialized nations. Despite major improvements in the …

The emerging field of regenerative cell therapy is still limited by the few cell types that can
reliably be differentiated from pluripotent stem cells and by the immune hurdle of …

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide.
Regenerative therapy has been applied to restore lost cardiac muscle and cardiac …

Cardiopoiesis-primed human stem cells exert sustained benefit in treating heart failure
despite limited retention following myocardial delivery. To assess potential paracrine …